filmov
tv
Frontline Targeted Therapy in ALK+ NSCLC
Показать описание
Robert C. Doebele, MD, PhD, reacts to decisions to treat a middle-aged woman with ALK-positive non–small cell lung cancer with alectinib up front versus other potential options.
0:02:41
0:45:52
0:01:45
0:06:51
0:06:36
0:02:04
0:01:42
0:11:38
0:01:22
0:03:04
0:01:05
0:01:17
0:45:52
0:01:06
0:00:58
0:03:13
0:05:31
0:17:55
0:06:41
0:33:52
0:20:24
0:00:55
0:05:30
0:00:41